Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 3/20 | 0.51 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847122 | 0.95 | BIRC5 (0.54) | CALM1BIRC5KDM4EATMMAPK1 | |
| SCHEMBL21621326 | 0.92 | KDM4E (0.62) | CALM1KDM4EATMMAPK1LMNA | |
| SCHEMBL2845384 | 0.89 | KDM4E (0.61) | CALM1BIRC5KDM4EATMMAPK1 | |
| SCHEMBL11911909 | 0.89 | BIRC5 (0.62) | CALM1BIRC5MAPK1ALDH1A1LMNA | |
| SCHEMBL15944034 | 0.85 | CALM1 (0.54) | CALM1BIRC5MAPK1ALDH1A1LMNA | |
| SCHEMBL8828240 | 0.83 | CYP1A2 (0.53) | CALM1BIRC5KDM4EATMMAPK1 | |
| SCHEMBL15693969 | 0.83 | BIRC5 (0.45) | CALM1BIRC5KDM4EATMMAPK1 | |
| SCHEMBL623585 | 0.81 | CALM1 (0.57) | CALM1BIRC5MAPK1ALDH1A1LMNA | |
| SCHEMBL5240461 | 0.81 | CSNK2A1 (0.51) | CALM1KDM4EMAPK1ALDH1A1LMNA | |
| SCHEMBL1251843 | 0.81 | KDM4E (0.77) | CALM1KDM4EATMMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | claimed |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2024-03-07 | — | — | US | claimed |
| WO-2023172497-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING COCAINE USE DISORDER | DREXEL UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2022-07-28 | — | — | US | claimed |
| US-10695302-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2020-06-30 | — | — | US | claimed |
| EP-3062791-B1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2020-01-08 | — | — | EP | claimed |
| CN-109745313-A | The D3 dopamine-receptor stimulant for treating dyskinesia in Parkinson's disease | 德雷克塞尔大学 | 2019-05-14 | — | — | CN | claimed |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2018-04-05 | — | — | US | claimed |
| US-9861594-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2018-01-09 | — | — | US | claimed |
| US-9675565-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2017-06-13 | — | — | US | claimed |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2016-09-08 | — | — | US | claimed |
| EP-3062791-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | Drexel University (US) | 2016-09-07 | — | — | EP | claimed |
| US-9289400-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2016-03-22 | — | — | US | claimed |
| WO-2015066019-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2015-05-07 | — | — | WO | claimed |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | claimed |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | claimed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | claimed |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695302-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | CHAT, ACHE, SLC18A3 | CALM1 842/4885BIRC5 1417/4885KDM4E 3097/4885 |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, COMT, SLC6A2 | CALM1 1061/4885BIRC5 1317/4885KDM4E 3034/4885 |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | CALM1 2251/4885BIRC5 2677/4885KDM4E 4017/4885 |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | CALM1 2251/4885BIRC5 2677/4885KDM4E 4017/4885 |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | CALM1 570/4885BIRC5 1294/4885KDM4E 2884/4885 |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | CALM1 570/4885BIRC5 1294/4885KDM4E 2884/4885 |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | CES2, CHAT, SLC18A2 | CALM1 475/4885BIRC5 3728/4885KDM4E 917/4885 |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | CALM1 2251/4885BIRC5 2677/4885KDM4E 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.